"We have found a new biomarker, the protein plectin, on cancer stem cells. We believe plectin may be a more common biomarker that could lead to broadly applicable drug development," reports Gomika Udugamasooriya in NatureScientific Reports. "Plectin is a structural protein, predominantly expressed intracellularly, but whose translocation onto the cell surface is linked to tumor invasion and metastasis."

All cancerous tumors contain a small subset of drug-resisting, self-renewing, and highly metastatic cells called tumor-initiating cells, or cancer stem cells, responsible for 90% of cancer deaths.

Udugamasooriya's process of discovering the biomarker and a drug-lead is different than conventional two-step discoveries, where researchers first find a biomarker and then develop a drug. He did both at once -- developing 400,000 potential synthetic chemical compounds (peptoids) and used them to capture the specific biomarker performing his unique, but simple two-color cell screen. From almost half a million, only three peptoids targeted cancer stem cells and not the remaining cancer cells from the same patient. When those peptoids were used to pulldown their targets, one of them was identified as plectin, proving that it is a unique biomarker for cancer stem cells.

"Our studies show both genotypic and phenotypic correlations between plectin and lung cancer stem cells, as well as association of high plectin expression with poor patient survival in lung adenocarcinoma, potentially identifying plectin as a biomarker for lung cancer stem cells," reports Udugamasooriya.

Because plectin assists in shaping cells, it is pivotal to the spread of cancer, helping cancer stem cells wend their way through the body.

"Scientists are desperately trying to find ways to handle these stubborn cancer stem cells to wipe out tumors. We predict this will be a more common drug target than current ones, because all tumors want to spread," he said.